Status: Recruiting
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.
Participants needed: 2,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Oxford Biodynamics Inc.Updated: Mar 17, 2025Locations: 3
Eligibility criteria
18 years of age or older [+6]
Pregnant or breastfeeding [+2]